论文部分内容阅读
目的通过探讨体外不同浓度50 nm葡聚糖包裹磁性纳米材料的致栓性,评价其作为药物载体的安全性。方法以PBS为对照组,将0.02 mg/ml、0.1 mg/ml、0.5 mg/ml浓度的磁性纳米颗粒与血浆或全血在体外共孵育,检测血小板聚集率、凝血功能、血凝块质量及血栓弹力图。结果 (1)PBS组、0.02 mg/ml SPIO组、0.1 mg/ml SPIO组及0.5 mg/ml SPIO组血小板聚集率分别为67.3±5.9%、68.3±4.5%、66.2±5.5%及69.5±5.9%(P>0.05);(2)4组的APTT值分别为28.1±2.7 S、28.5±2.4 S、28.2±2.5 S及29.1±3.6 S(P>0.05),PT值和TT值各组间也无统计学差异(P>0.05)。(3)血栓弹力图各参数(反应凝血功能的R时间、反应纤维蛋白原功能的K时间及α角、反应血小板功能的MA值、凝血综合指数CI),各组间比较差异均无显著性(P>0.05)。(4)4组的血凝块质量分别为759.6±38.7 mg、758.8±47.2 mg、769.8±39.2 mg和766.8±40.8 mg,组间比较无统计学差异(P>0.05)。结论 50 nm葡聚糖包裹磁性纳米材料在一定浓度范围内(0.02mg/ml-0.5mg/ml)对血小板聚集、凝血功能、血凝块质量及血栓弹力图均无明显影响,表明其无致栓性,血液相容性较好,可较为安全的应用于血栓性疾病的研究。
OBJECTIVE: To evaluate the safety of the drug as a drug carrier by investigating the thrombogenicity of magnetic nanomaterials coated with dextran at different concentrations of 50 nm in vitro. Methods With PBS as the control group, magnetic nanoparticles of 0.02 mg / ml, 0.1 mg / ml and 0.5 mg / ml were co-incubated with plasma or whole blood in vitro to detect the platelet aggregation rate, coagulation function, blood clot mass and Thrombus elasticity diagram. Results (1) The platelet aggregation rate of PBS group, 0.02 mg / ml SPIO group, 0.1 mg / ml SPIO group and 0.5 mg / ml SPIO group were 67.3 ± 5.9%, 68.3 ± 4.5%, 66.2 ± 5.5% and 69.5 ± 5.9 (P> 0.05). (2) The APTT values of the four groups were 28.1 ± 2.7 S, 28.5 ± 2.4 S, 28.2 ± 2.5 S and 29.1 ± 3.6 S, respectively There was no statistical difference (P> 0.05). (3) The parameters of thromboelastogram (R time of reaction coagulation function, K time and alpha angle of reaction fibrinogen function, MA value of reaction platelet function and coagulation index CI) showed no significant difference among the groups (P> 0.05). (4) The clot mass of the 4 groups were 759.6 ± 38.7 mg, 758.8 ± 47.2 mg, 769.8 ± 39.2 mg and 766.8 ± 40.8 mg, respectively. There was no significant difference between the two groups (P> 0.05). Conclusion 50 nm dextran-coated magnetic nanomaterials have no significant effect on platelet aggregation, coagulation function, blood clot mass and thrombus elasticity within a certain concentration range (0.02mg / ml-0.5mg / ml) Good suppository and blood compatibility, it can be more safely used in thrombotic diseases.